Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Virastatin (later renamed Larreastatin) is a natural product extract derived from the *Larrea tridentata* (creosote bush) plant using patented extraction and purification technologies. Developed by Global Botanics and trademarked by Larreacorp, it is a multifunctional ingredient characterized by antiviral, anti-inflammatory, antimicrobial, and antioxidant properties. The compound was primarily developed as a pharmaceutical ingredient for the suppression of herpes viruses, including genital herpes and shingles (herpes zoster). Clinical studies conducted in the mid-1990s reported high success rates in healing lesions in immunocompetent patients. While developed for pharmaceutical applications, it has been widely distributed as a dietary supplement under the brand name LarreaRx, often formulated in capsules and sometimes combined with Vitamin C.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Virastatin.